Premium
Erythropoietin in the treatment of delayed immune hemolysis of a major ABO‐incompatible bone marrow transplant
Author(s) -
López J.,
Steegmann J. L.,
Pérez G.,
Otero M. J.,
Berberana M.,
Cámara R.,
Lamana M.,
Villalta M. J. Fernández,
FernándezRañada J. M.
Publication year - 1994
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830450308
Subject(s) - hemolysis , abo blood group system , immunosuppression , medicine , immunology , bone marrow , immune system , erythropoietin
Delayed immune hemolysls can be observed after major ABO‐incompatible bone marrow transplants (BMT). The management of these hemolytic eplsodes Includes transfuslofi of group O red blood cells and increases of immunosuppression. Here we report the case of a 25‐year‐old patient who developed overt immune hemolysis on day +50 after a HLA‐identical ABO‐incompatible BMT. To avoid added immunosuppression, erythropoietin was started: an Increase in reticulocytes sufficlent to maintain hemoglobin despite perslstent hemolysis was observed. We conclude that erythropoletin may have a role In the management of delayed‐onset hemolysis of major ABO‐incompatible BMT, especially when added Immunosuppresslon is undesirable. © 1994 Wiley‐Liss, Inc.